The Senate Special Committee on Aging today concluded a two-part hearing on the impact of rising prescription drug costs on seniors and potential policy solutions.
 
Stacie Dusetzina, an associate professor of health policy at Vanderbilt University Medical Center in Nashville, Tenn., who participated on a National Academy of Medicine committee that issued a 2017 report on strategies for making prescription drugs more affordable, urged the Senate committee to focus on three key goals: ensuring that patients can access high-value drugs at reasonable out-of-pocket costs; removing incentives for high list prices and price increases; and rewarding true innovation by pharmaceutical companies by paying for value.

Also testifying at the hearing were representatives from Consumer Reports, Point-of-Care Partners and Horvath Health Policy.
 
The House Ways and Means Health Subcommittee also held a hearing today focused on promoting competition to lower Medicare drug prices. Witnesses included representatives from the Institute for Innovation Law at the University of California Hastings School of Law; Program on Regulation, Therapeutics and Law at Harvard Medical School; Global Health Justice Partnership at Yale Law School; Families USA; and American Action Forum.
 
AHA has recommended a number of policy solutions to restrain drug prices, from addressing anticompetitive actions by brand-name drug manufacturers to speeding up generic drug approvals and passing the CREATES Act.

Related News Articles

Headline
The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested comments for 60 days on market concentration and contracting…
Headline
The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote…
Headline
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in…
Headline
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar…
Headline
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price…
Headline
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation…